Vol 3, No 2 (2023)

Reimbursement Recommendations

Lumasiran (Oxlumo)

CADTH

Published February 27, 2023

PDF HTML

Pembrolizumab (Keytruda)

CADTH

Published February 22, 2023

PDF HTML

Durvalumab (Imfinzi)

CADTH

Published February 22, 2023

PDF HTML

Axicabtagene Ciloleucel (Yescarta)

CADTH

Published February 22, 2023

PDF HTML

Reimbursement Reviews

Guselkumab (Tremfya)

CADTH

Published February 27, 2023

PDF HTML

Mepolizumab (Nucala)

CADTH

Published February 27, 2023

PDF HTML

Edaravone Oral Suspension (Radicava)

CADTH

Published February 24, 2023

PDF HTML

Dalbavancin (Xydalba)

CADTH

Published February 23, 2023

PDF HTML

Pitolisant Hydrochloride (Wakix)

CADTH

Published February 22, 2023

PDF HTML

Ozanimod (Zeposia)

CADTH

Published February 21, 2023

PDF HTML

Pegvaliase (Palynziq)

CADTH

Published February 14, 2023

PDF HTML

Peer-Reviewed Article

Design, Rationale, and Preliminary Results of the Canadian Homozygous Familial Hypercholesterolemia Registry: 2008 to 2022 Update

Leslie Brown, Isabelle Ruel, Alexis Baass, Jean Bergeron, Liam R. Brunham, Lubomira Cermakova, Patrick Couture, Daniel Gaudet, Gordon A. Francis, Robert A. Hegele, Iulia Iatan, G.B. John Mancini, Brian W. McCrindle, Thomas Ransom, Mark H. Sherman, Ruth McPherson, Jacques Genest

Published February 10, 2023

PDF HTML

Health Technology Reviews

Dental Sealants for the Prevention of Dental Caries

Robyn Haas, Thyna Vu, Jennifer Horton

Published February 24, 2023

PDF HTML

Nabilone for the Treatment of Posttraumatic Stress Disorder: A 2023 Update

Calvin Young, Danielle MacDougall, Angie Hamson

Published February 23, 2023

PDF HTML

Bladder Scanners in Personal Care Homes

Qiukui Hao, Quenby Mahood

Published February 21, 2023

PDF HTML

Sotrovimab for the Treatment of COVID-19

Zahra Jafari, Danielle MacDougall

Published February 9, 2023

PDF HTML

Tenecteplase for Acute Ischemic Stroke

Khai Tran, Melissa Severn

Published February 8, 2023

PDF HTML

Specialized Clinics and Health Care Professional Resources for Post–COVID-19 Condition in Canada

Robyn Haas, Melissa Walter

Published February 6, 2023

PDF HTML

Horizon Scans

Wastewater Surveillance for Communicable Diseases

Michelle Clark, Melissa Severn

Published February 21, 2023

PDF HTML

View All Issues

Vol 3, No 2 (2023)

Reimbursement Recommendations

Lumasiran (Oxlumo)

Pembrolizumab (Keytruda)

Durvalumab (Imfinzi)

Axicabtagene Ciloleucel (Yescarta)

Anifrolumab (Saphnelo)

Brolucizumab (Beovu)

Dupilumab (Dupixent)

Deferiprone (Ferriprox)

Belimumab (Benlysta)

Dupilumab (Dupixent)

Cariprazine (Vraylar)

Reimbursement Reviews

Guselkumab (Tremfya)

Mepolizumab (Nucala)

Edaravone Oral Suspension (Radicava)

Dalbavancin (Xydalba)

Pitolisant Hydrochloride (Wakix)

Ozanimod (Zeposia)

Pegvaliase (Palynziq)

Cariprazine (Vraylar)

Entrectinib (Rozlytrek)

Pembrolizumab (Keytruda)

Tezepelumab (Tezspire)

Peer-Reviewed Article

Design, Rationale, and Preliminary Results of the Canadian Homozygous Familial Hypercholesterolemia Registry: 2008 to 2022 Update

Health Technology Reviews

Dental Sealants for the Prevention of Dental Caries

Nabilone for the Treatment of Posttraumatic Stress Disorder: A 2023 Update

Bladder Scanners in Personal Care Homes

Sotrovimab for the Treatment of COVID-19

Tenecteplase for Acute Ischemic Stroke

Specialized Clinics and Health Care Professional Resources for Post–COVID-19 Condition in Canada

Horizon Scans

Wastewater Surveillance for Communicable Diseases

Table of Contents

Reimbursement Recommendations

Reimbursement Reviews

Peer-Reviewed Article

Health Technology Reviews

Horizon Scans